EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Comprehensive analysis of MYB/MYBL1 -altered pediatric-type diffuse low-grade glioma

Daniel C Moreira iD, Ibrahim Qaddoumi, Susan Spiller, Thomas W Bouldin, Alan Davidson, Nasjla Saba-Silva, Daniel V Sullivan, Ryuma Tanaka, Aaron S Wagner, Matthew Wood, Paul Klimo, Godwin Job und 5 weitere

Neuro-Oncology · 2024

DOI: 10.1093/neuonc/noae048 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Daniel C Moreira und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioma, Proto-Oncogene Proteins c-myb. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, American Lebanese Syrian Associated Charities, V Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pediatric-type diffuse low-grade gliomas (pLGG) harboring recurrent genetic alterations involving MYB or MYBL1 are closely related tumors. Detailed treatment and outcome data of large cohorts are still limited. This study aimed to comprehensively evaluate pLGG with these alterations to define optimal therapeutic strategies.

Methods

We retrospectively reviewed details of pLGG with MYB or MYBL1 alterations from patients treated or referred for pathologic review at St. Jude Children’s Research Hospital. Tumor specimens were centrally reviewed, and clinical data were collated.

Results

Thirty-three patients (18 male; median age, 5 years) were identified. Two tumors had MYBL1 alterations; 31 had MYB alterations, MYB::QKI fusion being the most common (n = 10, 30%). Most tumors were in the cerebral hemispheres (n = 22, 67%). Two patients (6%) had metastasis at diagnosis. The median follow-up was 6.1 years. The 5-year event-free survival (EFS) rate was 81.3% ± 8.3%; the 5-year overall survival (OS) rate was 96.4% ± 4.1%. Patients receiving a near-total or gross-total resection had a 5-year EFS of 100%; those receiving a biopsy or subtotal resection had a 5-year EFS rate of 56.6% ± 15.2% (P < .01). No difference in EFS was observed based on location, histology, or molecular alterations. However, the tumors that progressed or metastasized may have distinct methylation profiles with evidence of activation of the MAPK and PI3K/AKT/mTOR pathways. Conclusions pLGG with MYB/MYBL1 alterations have good outcomes. Our findings suggest that surgical resectability is a crucial determinant of EFS. Further characterization is required to identify optimal treatment strategies for progressive tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsGliomaProto-Oncogene Proteins c-mybChildChild, PreschoolFemaleHumansMaleBiomarkers, TumorFollow-Up StudiesNeoplasm GradingPrognosisProto-Oncogene ProteinsRetrospective StudiesSurvival RateTrans-Activators

Stichwörter der Autor:innen

MYB/MYBL1 alterationsoutcomepediatric diffuse low-grade gliomasurvivaltreatment

Substanzen

Biomarkers, TumorMYB protein, humanMYBL1 protein, humanProto-Oncogene ProteinsProto-Oncogene Proteins c-mybTrans-Activators

Autor:innen und Institutionen

  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Pediatric Hematology/Oncology, East Tennessee Children's Hospital, Knoxville, Tennessee, USA.
  • Department of Pathology, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Department of Pediatric Hematology/Oncology, Red Cross War Memorial Children's Hospital, Cape Town, South Africa.
  • Department of Pediatric Oncology, Grupo de Apoio ao Adolescente e à Criança com Câncer (GRAACC), São Paulo, Brazil.

ORCID-Profile: Daniel C Moreira, Jason Chiang

Förderung

  • NCI NIH HHS
  • American Lebanese Syrian Associated Charities
  • V Foundation
  • National Cancer Institute

Zitieren

APA

Moreira, D. C., Qaddoumi, I., Spiller, S., Bouldin, T. W., Davidson, A., Saba-Silva, N., Sullivan, D. V., Tanaka, R., Wagner, A. S., Wood, M., Klimo, P., Job, G., Devidas, M., Li, X., Gajjar, A., Robinson, G. W., & Chiang, J. (2024). Comprehensive analysis of MYB/MYBL1 -altered pediatric-type diffuse low-grade glioma. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae048

Vancouver

Moreira DC, Qaddoumi I, Spiller S, Bouldin TW, Davidson A, Saba-Silva N, et al. Comprehensive analysis of MYB/MYBL1 -altered pediatric-type diffuse low-grade glioma. Neuro-Oncology. 2024. doi:10.1093/neuonc/noae048

BibTeX
@article{Moreira2024,
  author = {Moreira, Daniel C and Qaddoumi, Ibrahim and Spiller, Susan and Bouldin, Thomas W and Davidson, Alan and Saba-Silva, Nasjla and Sullivan, Daniel V and Tanaka, Ryuma and Wagner, Aaron S and Wood, Matthew and Klimo, Paul and Job, Godwin and Devidas, Meenakshi and Li, Xiaoyu and Gajjar, Amar and Robinson, Giles W and Chiang, Jason},
  title = {Comprehensive analysis of MYB/MYBL1 -altered pediatric-type diffuse low-grade glioma},
  journal = {Neuro-Oncology},
  year = {2024},
  doi = {10.1093/neuonc/noae048}
}
Kostenlos starten →